ReviewThe Lancet. Infectious diseases2015
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.
Review in The Lancet. Infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Journal of child health care : for professionals working with children in the hospital and community · 2022Trial
- Trials, tribulations, and formulations in access to new TB drugs for children: learning from rifapentine.IJTLD open · 2026Review
- Fixed Dose Combinations as an Advantage for the Treatment of Pediatric Tuberculosis: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Is Short Therapy an Appropriate Regimen for Children and Young Adolescents with Drug-Susceptible Tuberculosis?Pharmaceuticals (Basel, Switzerland) · 2026Review
- Maternal-Child Human Immunodeficiency Virus Clinical Trials Networks across the Ages.Clinics in perinatology · 2024Review
- Target regimen profiles for tuberculosis treatment.Bulletin of the World Health Organization · 2024Article
- Facilitators and barriers to adolescent participation in a TB clinical trial.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2024Article
- Vulnerability, social value and the equitable sharing of benefits from research: beyond the placebo and access debates.Frontiers in medicine · 2024Article
- Caring for Adolescents and Young Adults With Tuberculosis or at Risk of Tuberculosis: Consensus Statement From an International Expert Panel.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2023Article
- Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.Frontiers in cellular and infection microbiology · 2023Review
- Paediatric formulations for the treatment of drug resistant TB: closing the gaps.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Article
- Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities.Pathogens (Basel, Switzerland) · 2022Article
- Profiling Clinical Research Activity at an Academic Medical Center by Using Institutional Databases: Content Analysis.JMIR public health and surveillance · 2020Article
- Advances in clinical trial design: Weaving tomorrow's TB treatments.PLoS medicine · 2020Review
- Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019Article
- Article
- Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2019Article
- Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Tuberculosis in Children.Pediatric clinics of North America · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally effective, are hampered by high pill burden, long duration of treatment, coexistent toxic effects, and an overall scarcity of suitable child-friendly formulations. Several new drugs and regimens with promising activity against both drug-susceptible and drug-resistant strains have entered clinical development and are either in various phases of clinical investigation or have received marketing authorisation for adults; however, none have data on their use in children. This consensus statement, generated from an international panel of opinion leaders on childhood tuberculosis and incorporating reviews of published literature from January, 2004, to May, 2014, addressed four key questions: what drugs or regimens should be prioritised for clinical trials in children? Which populations of children are high priorities for study? When can phase 1 or 2 studies be initiated in children? What are the relevant elements of clinical trial design? The consensus panel found that children can be included in studies at the early phases of drug development and should be an integral part of the clinical development plan, rather than studied after regulatory approval in adults is obtained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.